Quest Diagnostics (DGX) PT Lowered to $98 at Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser lowered the price target on Quest Diagnostics (NYSE: DGX) to $98.00 (from $101.00) while maintaining a Overweight rating.
Morgan Stanley analyst Ricky Goldwasser lowered the price target on Quest Diagnostics (NYSE: DGX) to $98.00 (from $101.00) while maintaining a Overweight rating.